In this video, health-care analyst David Williamson discusses the day's three biggest losers in the sector, including Novo Nordisk, which dropped more than 8% in advance of its FDA advisory committee meeting for long-acting insulin Tresiba on Thursday. Watch and find out why investors are feeling glum after reading the FDA's briefing documents and catch up on the day's other big movers.